|
NOROVIRUS
Norovirus is the leading cause of infectious gastroenteritis in developed countries worldwide. Outbreaks of the virus are very common in long-term care facilities, hospitals and schools, and complications related to the infection can include organ dysfunction or even death. LigoCyte has developed a first-in-class VLP vaccine against norovirus that is currently undergoing human testing.
|
|
|
|
|
respiratory viruses
LigoCyte is developing vaccines against two of the most common causes of respiratory viral infections, respiratory syncytial virus and influenza. Both programs are based on the company’s proprietary virus-like particle technology, and each has achieved animal proof-of-principle against virus challenge in gold-standard models of infection. |
|
|
|
|
COMPANY
LigoCyte is a clinical-stage biologic drug development company focused on respiratory and gastrointestinal indications. The company’s virus-like particle (VLP) vaccine technologies support products that induce robust immune responses to prevent serious infections. |
|
|
|
